Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, ...
A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in ...
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating ...
Zacks Investment Research on MSN
Biodesix expands MRD testing with tumor-informed and tumor-naive tests
Biodesix BDSX recently announced strategic progress in two molecular residual disease (MRD) programs to expand access to ...
Machine-learning prediction of 30-, 90-, and 180-day readmissions in head and neck cancer using a national readmission database. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
A pharmacist explored how recent NCCN guideline updates leverage ctDNA MRD testing to guide adjuvant immunotherapy and improve EFS in bladder cancer. The latest NCCN guideline updates for bladder ...
Mamta Parikh, MD, MS, contextualized recent NCCN updates on ctDNA MRD testing after radical cystectomy in muscle-invasive bladder cancer. She emphasized that while ctDNA holds significant prognostic ...
In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of ...
(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...
Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results